Spotlight on global cancer control at ASCO 2022

UICC announces global coalition to increase access to essential cancer medicines in low and lower middle-income countries

ASCO 2022: Highlights and analysis

ctDNA sequencing detects outcomes for pretreated advanced gastrointestinal stromal tumour

FOLFOXIRI plus panitumumab vs mFOLFOX6/PAN for unresectable RAS and BRAF wild-type mCC

Comment: Panitumumab plus mFOLFOX6 improves OS for RAS wild-type left sided mCRC

Comment:Trifluridine/tipiracil, bevacizumab + trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Trifluridine/tipiracil plus bevacizumab and trifluridine/tipiracil provides benefits for metastatic colorectal cancer patients

Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Circulating tumour DNA analysis can help identify the need for adjuvant therapy in stage II colon cancer

Novel bispecific checkpoint inhibitor MEDI5752 shows promise for advanced solid tumours